ArticleTranslational lung cancer research2026
Association between oxidative stress index and lung cancer risk in idiopathic pulmonary fibrosis: an exploratory retrospective analysis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a significant risk factor for lung cancer. However, early detection is often hindered by background fibrotic changes. This study assessed whether the oxidative stress index (OSI), which reflects the balance between systemic oxidative stress and antioxidant capacity, is associated with lung cancer development in patients with IPF. Methods: We retrospectively analyzed 90 patients with newly diagnosed IPF. Serum levels of derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) were measured at diagnosis to calculate the OSI (100 × d-ROMs/BAP). Using a 1-year landmark approach (n=83), the primary endpoint was lung cancer development during the follow-up period. Results: Fifteen patients (18.1%) developed lung cancer. Although individual d-ROMs showed no significant differences between cohorts, the baseline OSI was significantly higher in the lung cancer group than in the non-lung cancer group (P<0.001). Receiver operating characteristic analysis demonstrated high discriminative capacity of the OSI (area under the curve: 0.857), with an optimal cut-off of 14.39. Multivariate Cox regression analysis indicated an independent association between the OSI and lung cancer development, even after adjusting for antifibrotic use and macrophage proportion in bronchoalveolar lavage fluid (BALF). Notably, the OSI did not significantly predict all-cause mortality, suggesting its relative specificity for carcinogenesis in this population. Conclusions: Baseline OSI may serve as a potential biomarker associated with future lung cancer development in patients with IPF, independent of antifibrotic agent use and BALF macrophage proportion. Further large-scale prospective studies are needed to validate whether OSI-guided risk stratification can help optimize surveillance strategies for this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.